Fluconazole to prevent yeast infections in bone marrow transplantation patients: A randomized trial of high versus reduced dose, and determination of the value of maintenance therapy

American Journal of Medicine

Volumn 112, Issue 5, 2002, Pages 369-379

  MacMillan, Margaret L ^a,b   Goodman, Jesse L ^b   DeFor, Todd E ^b   Weisdorf, Daniel J ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; FLUCONAZOLE; NYSTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION PREVENTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CLOTRIMAZOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS;

EID: 0036532505     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)01127-5     Document Type: Article

References (28)

1. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation
2. Candida infections in bone marrow transplant recipients
3. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: Results of a 5-year retrospective study
4. Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome
5. Late infections after allogeneic bone marrow transplantation: Comparison of incidence in related and unrelated donor transplant recipients
6. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients
7. Experimental basis for usage of fluconazole for prevention or early treatment of disseminated candidiasis in granulocytopenic hosts
8. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
9. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized double-blind study
10. Prolonged fluconazole is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
11. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis
12. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
13. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
14. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation
15. Fluconazole and Candida krusei fungemia
16. Candida parapsilopsis fungemias in bone marrow transplant recipients: Implications for azole prophylactic therapy
17. Non-parametric estimation from incomplete observations
18. Regression models and life tables
19. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: A multivariate analysis of risk factors
20. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
21. Risk factors for fungal infections in patients with malignant hematologic disorders: Implications for empirical therapy and prophylaxis
22. Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia
23. Granulocyte colony-stimulating factor administered in vivo augments neutrophil-mediated activity against opportunistic fungal pathogens
24. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia
25. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis
26. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor
27. G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis